EUCTR2017-002499-14-ES进行中（未招募）1 期
A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 933
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1
- •- Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)
- •- Treatment-naïve participants (no prior systemic anticancer therapy for unresectable or metastatic melanoma)
- •- Measurable disease
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 28
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 634
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 271
排除标准
- •- Active brain metastases or leptomeningeal metastases
- •- Uveal or ocular melanoma
- •- Participants with active, known, or suspected autoimmune disease
- •- Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
研究者
相似试验
进行中（未招募）
1 期
An Investigational Immuno-therapy Study of BMS-986205 Combined with Nivolumab, Compared to Nivolumab by itself, in Patients with Advanced MelanomaMetastatic or Unresectable Melanoma that is Previously UntreatedMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2017-002499-14-DEBristol-Myers Squibb International Corporation933
进行中（未招募）
1 期
An Investigational Immuno-therapy Study of BMS-986205 Combined withNivolumab, Compared to Nivolumab by itself, in Patients with AdvancedMelanomaEUCTR2017-002499-14-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO20
已完成
3 期
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaMelanomaJPRN-jRCT2080223779Bristol-Myers Squibb K.K.700
进行中（未招募）
1 期
An Investigational Immuno-therapy Study of BMS-986205 Combined with Nivolumab, Compared to Nivolumab by itself, in Patients with Advanced MelanomaMetastatic or Unresectable Melanoma that is Previously UntreatedMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2017-002499-14-GRBristol-Myers Squibb International Corporation20
进行中（未招募）
1 期
An Investigational Immuno-therapy Study of BMS-986205 Combined with Nivolumab, Compared to Nivolumab by itself, in Patients with Advanced MelanomaMetastatic or Unresectable Melanoma that is Previously UntreatedMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2017-002499-14-PLBristol-Myers Squibb International Corporation933